Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- 5-(4-chlorophenyl)-N-[4-(1-piperazinyl)phenyl]-N-(2-pyridinylmethyl)-2-furancarboxamide, monohydrochloride
- Correlated keywords
- 1314118-92-7 p38/mitogen-activated proteins kinase-activated 2 MAPKAPK2 MK2 inhibitors cytokines inflammation mitogens activated kinases MAPKAPK-2 MAPKAPK 2 MK-2 MKs 2 MK-25 MK25 25 inhibits inhibitions non-ATP non ATP nonATP pro-inflammatory proinflammatory pro inflammatory secretions THP1 THP-1 THPs 1 acute monocytic leukemias cells lines LPS-stimulated LPS stimulated stimulates TNF? IL-6 IL6 ILs 6 IL1? MMP matricmetalloprotease 13 SW1352 chondrosarcomas chondrocytes cultures SW-1353 SWs 1353 pathways diseases competitive adenosines triphosphates humans tumors necrosis factors TNF-a TNF-alpha TNF-.alpha. interleukins interleukin-6 interleukin-1b interleukin-1beta interleukin-1? interleukin-1.beta. primary
- Product Overview:
Activation of the p38/mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2 or MK2) pathway has been implicated in promoting pro-inflammatory cytokine production and related inflammatory diseases. MK2 inhibitor IV is a highly selective, non-ATP competitive MK2 inhibitor with an IC50 value of 0.11 ?M.{22830} MK2 inhibitor IV has been shown to inhibit pro-inflammatory cytokine secretion from the human THP-1 acute monocytic leukemia cell line, causing inhibition of LPS-stimulated TNF-? (IC50 = 4.4 ?M) and IL-6 (IC50 = 5.2 ?M) secretion.{22830} It can also inhibit IL-1?-stimulated matrixmetalloprotease 13 secretion from the SW1353 chondrosarcoma cell line (IC50 = 5.7 ?M) and human primary chondrocyte cultures (IC50 = 2.2 ?M).{22830}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.